



EPH and Ephrins in Pathogenesis and as Drug Target

Guest Editors:

Dr. Massimiliano Tognolini

Department of Food and Drug,
University of Parma, 43124
Parma, Italy

Prof. Dr. Jiangping Wu

Centre Hospitalier de L'Universite
de Montreal, University of
Montreal, Montreal, QC, Canada

Dr. Carmine Giorgio

Department of Food and Drug,
University of Parma, 43124
Parma, Italy

Deadline for manuscript
submissions:

closed (23 December 2023)

Message from the Guest Editors

Thirty-five years later the discovery of the first EPH gene by Takaku's group, Eph receptors and the ephrin ligands constitute a complex and redundant cellular communication network.

Nowadays a wide plethora of biological techniques and pharmacological tools are available to investigate the roles and the potential benefits of Eph/ephrin targeting in several diseases. Unfortunately, despite the research efforts, drugs targeting this system have not reached the market yet, and the gap between the bench and the bed still exists.

The present Special Issue of Pharmaceuticals aims to be not only a synthesis of the meeting Eph/ephrin system (www.ephrins.org) we recently organized, but also an opportunity for all the scientists in this field. This special issue purposes to collect the most updated works and to be a valid source of inspiration for future research in the field of Eph/ephrin targeting.

We sincerely hope that you will be able to submit your original contributions in this Special Issue, that want to be a valuable piece of the state of the art on Eph/ephrin targeting puzzle.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande, Edifício C8, 5º Piso, 1749-016 Lisboa, Portugal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPus / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q2 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Pharmaceutical Science*)

Contact Us

Pharmaceuticals Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceuticals
pharmaceuticals@mdpi.com